In vitro treatment with trabectedin decreased the production of CCL2, CXCL8, IL-6, VEGF and PTX3 by myxoid liposarcoma (MLS) primary tumor cultures and/or cell lines, and freshly isolated ovarian cancer cells from ascites (19, 39). This evidence concerns the gene CXCL8 and neoplasm.